



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/645,401	08/21/2003	Margaret Y. Chu-Moyer	PC10124D	7739
28523	7590	04/08/2004	EXAMINER	
PFIZER INC. PATENT DEPARTMENT, MS8260-1611 EASTERN POINT ROAD GROTON, CT 06340			PATEL, SUDHAKER B	
			ART UNIT	PAPER NUMBER
			1624	

DATE MAILED: 04/08/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/645,401	CHU-MOYER ET AL.
	Examiner	Art Unit
	Sudhaker B. Patel, D.Sc.Tech.	1624

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 21 August 2003.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 165 and 166 is/are pending in the application.
4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 165, 166 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date 8/21/03.

4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. 3/26/04 .
5) Notice of Informal Patent Application (PTO-152)
6) Other: _____.

DETAILED ACTION

Applicants' communication paper dated 8/21/03 is acknowledged. Applicants have cancelled claims 1-164, 167-188. Therefore, claims in this application are the claims 165,166 only. Claim 165 is very generic and includes entire specification without disclosing the specific and exact structures of the compounds. Also, there is an overlap of the subject matter with U.S.P. 6414149/6602875. See interview summary dated 3/26/04 enclosed with this communication.

First action on merits follows.

Information Disclosure Statement

1. The information disclosure statement (IDS) submitted on 8/21/03 is being considered by the examiner. A signed copy of the PTO Form 1449 is enclosed with this communication for applicants' record.

Double Patenting

2. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claim165 is rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim1 of U.S. Patent No. 6414149. Although the conflicting claims are not identical, they are not patentably distinct from each other because the ref. '959 claim 1 recites the compound of Formula I wherein R3 radical = R3a, and the definitions of various components for the ref. '149 overlap with the instant claim 165. See ref.'149 claim 1 in columns 200-203.

Instant claim 165 differs from above claim by reciting a broader genus but they also read onto the ref.'149 claims, which would extent, the monopoly of the U.S.P.6414149.

Claim165 is rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim1 of U.S. Patent No. 6602875. Although the conflicting claims are not identical, they are not patentably distinct from each other because the ref. '875 claim 1 recites the compound of Formula I wherein R3 radical = R3a, R3b and the definitions of various components for the ref. '875 overlap with the instant claim 165. See ref.'875 claim 1 in columns 189-193.

Instant claim 165 differs from above claim by reciting a broader genus but they also read onto the ref.'875 claims, which would extent, the monopoly of the U.S.P.6602875.

Claim Rejections - 35 USC § 112

3. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.


Claim 165 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite in that it fails to point out what is included or excluded by the claim language. This claim is an omnibus type claim.

Claim 165 recites the generic nature of the invention as presented in the specification. The definition included for R3 component represent structures R3a – R3q representing open-ended straight bridge(s), cycloalkyl with heteroatom(s), spiro-compounds, mono-, bi-, tri cyclic heterocycles, and variables R1-R45 with integers k, m, n, r, q. The provisos provided are not limiting the subject matter already allowed in the patents already granted. See rejections above.

Allowable Subject Matter

4. Claim166 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
5. The following is a statement of reasons for the indication of allowable subject matter: The closest prior art ref. Geisen et al (Chemical Abstract DN 116:194353, also cited as EP 470616) teaches pyrimidine derivatives with a core: " 2-MeOCH₂-pyrimidine-4-OH wherein R4-OH can be modified to piperazine ring having 4"-NR. R of piperazine of the ref. '616 can be CHO, COR₃, SO₂R₃, SO₂NMe₂, which are different for the instant claim(s).
6. The ref.'616 does not suggest or indicate to arrive at the instant compounds.
7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sudhaker B. Patel, D.Sc.Tech. whose telephone number is (571) 272-0671.
8. The examiner can normally be reached on 6:30 to 5:00 pm (Monday-Thursday). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Mukund J. Shah can be reached on (571) 272 0674 or Sr. Examiner Mr. Richard Raymond at (571) 272 0673 or Mr. James Wilson at (571) 272-0661.
9. The fax phone numbers for the organization where this application or proceeding is assigned are 703 308 4556 for regular communications and 703 308 4556 for After Final communications.

10. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703 308 1235. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Sudhaker B. Patel, D.Sc. Tech.
March 26, 2004

Mukund J. Shah 3/26/04
MUKUND SHAH
SUPERVISORY PATENT
EXAMINER
ART UNIT 1624/1623